AbbVie Inc. Files Definitive Proxy Statement for 2024 Annual Meeting

Ticker: ABBV · Form: DEF 14A · Filed: Mar 18, 2024 · CIK: 1551152

Abbvie Inc. DEF 14A Filing Summary
FieldDetail
CompanyAbbvie Inc. (ABBV)
Form TypeDEF 14A
Filed DateMar 18, 2024
Risk Level
Pages15
Reading Time18 min
Key Dollar Amounts$54.3B, $39.9B, $22.8B, $7.8B, $1.0B
Sentimentneutral

Sentiment: neutral

Topics: AbbVie, DEF 14A, Proxy Statement, Executive Compensation, Shareholder Meeting

TL;DR

<b>AbbVie Inc. has filed its Definitive Proxy Statement detailing executive compensation and corporate governance matters for the upcoming annual meeting.</b>

AI Summary

AbbVie Inc. (ABBV) filed a Proxy Statement (DEF 14A) with the SEC on March 18, 2024. AbbVie Inc. filed a Definitive Proxy Statement (DEF 14A) on March 18, 2024. The filing covers the period ending May 3, 2024. The company's principal executive offices are located at 1 North Waukegan Road, North Chicago, IL 60064. The filing includes information related to executive compensation for the fiscal year ending December 31, 2023. The document pertains to the company's 1934 Act filings.

Why It Matters

For investors and stakeholders tracking AbbVie Inc., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions on proposals at the annual meeting. As a DEF 14A, it provides detailed information on corporate governance, director nominations, and other shareholder-related matters, impacting the company's operational and strategic direction.

Risk Assessment

Risk Level: — AbbVie Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material events or financial distress indicators.

Analyst Insight

Review the executive compensation details and any shareholder proposals to inform voting decisions for the upcoming annual meeting.

Key Numbers

  • 2024-03-18 — Filing Date (DEF 14A filing date)
  • 2024-05-03 — Period of Report (Conformed period of report)
  • 2023-12-31 — Fiscal Year End (Company fiscal year end)

Key Players & Entities

  • AbbVie Inc. (company) — Registrant name
  • 1 North Waukegan Road, North Chicago, IL 60064 (location) — Business and mailing address
  • 2024-03-18 (date) — Filing date
  • 2024-05-03 (date) — Period of report
  • 1934 Act (regulation) — SEC Act

FAQ

When did AbbVie Inc. file this DEF 14A?

AbbVie Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 18, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by AbbVie Inc. (ABBV).

Where can I read the original DEF 14A filing from AbbVie Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by AbbVie Inc..

What are the key takeaways from AbbVie Inc.'s DEF 14A?

AbbVie Inc. filed this DEF 14A on March 18, 2024. Key takeaways: AbbVie Inc. filed a Definitive Proxy Statement (DEF 14A) on March 18, 2024.. The filing covers the period ending May 3, 2024.. The company's principal executive offices are located at 1 North Waukegan Road, North Chicago, IL 60064..

Is AbbVie Inc. a risky investment based on this filing?

Based on this DEF 14A, AbbVie Inc. presents a moderate-risk profile. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material events or financial distress indicators.

What should investors do after reading AbbVie Inc.'s DEF 14A?

Review the executive compensation details and any shareholder proposals to inform voting decisions for the upcoming annual meeting. The overall sentiment from this filing is neutral.

How does AbbVie Inc. compare to its industry peers?

AbbVie Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of advanced therapies.

Are there regulatory concerns for AbbVie Inc.?

The filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.

Industry Context

AbbVie Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of advanced therapies.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.

What Investors Should Do

  1. Review the detailed executive compensation breakdown for named executive officers.
  2. Examine the proposals to be voted on at the annual meeting, including director elections and any advisory votes on executive compensation.
  3. Understand the company's corporate governance practices as outlined in the proxy statement.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure for proxy solicitation and does not represent a change from previous filings of this type.

Filing Stats: 4,386 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2024-03-18 16:15:49

Key Financial Figures

  • $54.3B — rm Net Revenues Operating Cash Flow $54.3BN $39.9BN $22.8BN -6.4% compared t
  • $39.9B — enues Operating Cash Flow $54.3BN $39.9BN $22.8BN -6.4% compared to 2022* +
  • $22.8B — erating Cash Flow $54.3BN $39.9BN $22.8BN -6.4% compared to 2022* +8.4% compa
  • $7.8B — nvestment Development Pipeline 12 $7.8BN ~90 assets with 2023 net revenues
  • $1.0B — ~90 assets with 2023 net revenues > $1.0BN increased $0.7BN compared to 2022***
  • $0.7B — h 2023 net revenues > $1.0BN increased $0.7BN compared to 2022*** active clinical a
  • $54.3 b — ional execution Total net revenues of $54.3 billion, driven by strong performance fro
  • $39.9 b — e drove Growth Platform net revenues of $39.9 billion, an increase of 8.4% compared to
  • $2.72 — r U.S. Humira. Reported diluted EPS of $2.72 on a GAAP basis and adjusted diluted EP
  • $11.11 — GAAP basis and adjusted diluted EPS of $11.11. See Appendix B for the reconciliation.
  • $22.8 billion — tion. Generated operating cash flow of $22.8 billion. Advancing new medicines with an inno
  • $190B — Increase Total Stockholder Return +$190BN >285% +343% 10-year increase, ad
  • $1.55 — ignificant stockholder value raised to $1.55 per share from $0.40 per share over the
  • $0.40 — r value raised to $1.55 per share from $0.40 per share over the last decade over th
  • $7.8 billion — r material areas. Product Innovation $7.8 billion in adjusted research & development inve

Filing Documents

Executive Compensation Highlights

Executive Compensation Highlights 12 INFORMATION CONCERNING DIRECTOR NOMINEES 13 THE BOARD OF DIRECTORS AND ITS COMMITTEES 21 COMMUNICATING WITH THE BOARD OF DIRECTORS 28 DIRECTOR COMPENSATION 29 SECURITIES OWNERSHIP 31

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 33 Compensation Discussion and Analysis 33 Compensation Committee Report 51 Compensation Risk Assessment 51 Summary Compensation Table 53 2023 Grants of Plan-Based Awards 56 2023 Outstanding Equity Awards at Fiscal Year End 58 2023 Option Exercises and Stock Vested 61 Potential Payments upon Termination or Change in Control 70 RATIFICATION OF ERNST & YOUNG LLP AS ABBVIE'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 73 AUDIT INFORMATION 74 Audit Fees and Non-Audit Fees 74 Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Registered Public Accounting Firm 74 Audit Committee Report 75 SAY ON PAY—ADVISORY VOTE ON THE APPROVAL OF EXECUTIVE COMPENSATION 76 SAY WHEN ON PAY—ADVISORY VOTE ON THE FREQUENCY OF FUTURE APPROVALS OF EXECUTIVE COMPENSATION 77 MANAGEMENT PROPOSAL TO ELIMINATE SUPERMAJORITY VOTING 78 STOCKHOLDER PROPOSALS 80 Stockholder Proposal on Simple Majority Vote 80 Stockholder Proposal on Lobbying 81 Stockholder Proposal on Patent Process 85 ADDITIONAL INFORMATION 89 INFORMATION ABOUT THE ANNUAL MEETING 93 Who Can Vote 93 Notice and Access 93 Voting by Proxy 93 Revoking a Proxy 93 Discretionary Voting Authority 93 Quorum 94 Votes Required for Each Item 94 Inspectors of Election 95 Cost of Soliciting Proxies 95 AbbVie Savings Plan 95 f Table of Contents PROXY SUMMARY About the Meeting This proxy statement and the accompanying proxy are being made available to stockholders on or about March 18, 2024. The accompanying proxy is solicited on behalf of the Board of Directors for use at the Annual Meeting of Stockholders. This summary highlights selected information in the proxy statement. Please review the entire proxy statement and the AbbVie 2023 Annual Report before voting. The voting items expected to be proposed at the meeting are listed below along with the board's votin

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.